Mabthera Sc 1400 Mg 120 mg Solution for subcutaneous injection
PDF Leaflet Revision Date: 11 Oct 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of Non-Hodgkinu2019s lymphoma (NHL).
Dosage (summary)
1400 mg subcutaneously once weekly for 3 weeks after initial IV dose.
Special Populations
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Fludarabine
- Cyclophosphamide
- Methotrexate
Contraindications
- Hypersensitivity to rituximab
- Active severe infections
- Severe heart failure
- Severely immunocompromised state
Common side effects
- Infusion-related reactions
- Injection site reactions
- Infections
Counselling Points
- Premedicate with analgesics and antihistamines
- Monitor for infusion reactions
- Avoid live vaccines during treatment
Serious warnings
- Infusion-related deaths
- Tumour Lysis Syndrome
- Progressive Multifocal Leukoencephalopathy (PML)
Important Disclaimer
The Mabthera Sc 1400 Mg 120 mg Solution for subcutaneous injection professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
